Clinical Trial of the Week: Treatment trial for patients with recurrent, persistent or metastatic endometrial cancer

By Donna Loyle, communications specialist, LIMR

Main Line Health researchers seek patients diagnosed with recurrent, persistent or metastatic endometrial cancer for a randomized phase II clinical trial comparing the experimental drug cediranib, the FDA-approved therapy olaparib, and the combination of the two drugs.

Participants are randomized into three treatment groups:

  • Arm 1: cediranib maleate, which is a drug that may help keep cancer cells from growing by affecting their blood supply
  • Arm 2: Lynparza® (olaparib), a targeted therapy currently approved for patients diagnosed with recurrent ovarian or breast cancer
  • Arm 3: both of those drugs

Inclusion criteria:

  • Must have evaluable disease as defined by RECIST 1.1
  • Tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
  • Must have had one prior chemotherapy for management of endometrial carcinoma, but must not have received any non-cytotoxic chemotherapy for management of recurrent or persistent disease; prior hormonal therapy is allowed
  • Patients must have adequately controlled blood pressure and be willing and able to record their daily blood pressure readings

Study #NRG GY012 is approved for Lankenau Medical Center and Paoli Hospital. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit https://www.mainlinehealth.org/research/clinical-trials/nrg-gy012

This entry was posted in Clinician News and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published.